Brevan Howard Capital Management LP Grows Holdings in Intuitive Surgical, Inc. $ISRG

Brevan Howard Capital Management LP lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 895.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,988 shares of the medical equipment provider’s stock after acquiring an additional 9,884 shares during the quarter. Brevan Howard Capital Management LP’s holdings in Intuitive Surgical were worth $4,914,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ISRG. SteelPeak Wealth LLC lifted its holdings in Intuitive Surgical by 28.7% during the third quarter. SteelPeak Wealth LLC now owns 41,993 shares of the medical equipment provider’s stock valued at $18,781,000 after purchasing an additional 9,364 shares in the last quarter. Atlantic Union Bankshares Corp raised its position in shares of Intuitive Surgical by 19.3% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 22,759 shares of the medical equipment provider’s stock worth $10,179,000 after purchasing an additional 3,676 shares during the last quarter. World Investment Advisors raised its position in shares of Intuitive Surgical by 238.3% during the 3rd quarter. World Investment Advisors now owns 5,399 shares of the medical equipment provider’s stock worth $2,415,000 after purchasing an additional 3,803 shares during the last quarter. E. Ohman J or Asset Management AB lifted its stake in Intuitive Surgical by 4.1% in the 3rd quarter. E. Ohman J or Asset Management AB now owns 28,306 shares of the medical equipment provider’s stock valued at $12,659,000 after buying an additional 1,123 shares in the last quarter. Finally, Valley Wealth Managers Inc. boosted its holdings in Intuitive Surgical by 52.7% in the 3rd quarter. Valley Wealth Managers Inc. now owns 4,084 shares of the medical equipment provider’s stock worth $1,826,000 after buying an additional 1,409 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clearance expands da Vinci 5 into cardiac surgery, opening a much larger long-term TAM (management cites a jump from ~17k to ~160k addressable procedures in cleared markets) — a multi-year growth driver for procedure volume and consumables. Read More.
• Positive Sentiment: Completed acquisition of Southern Europe distributor businesses (Italy, Spain, Portugal) shifts da Vinci and Ion sales to direct operations — should improve control of regional sales/service and capture margin/recurring revenue over time. Read More.
• Positive Sentiment: Sell-side momentum: Citigroup upgraded ISRG to Buy and several analysts maintain bullish price targets, supporting upside thesis and sentiment. Read More.
• Positive Sentiment: Recent Q4 results beat consensus (strong revenue and EPS growth), reinforcing recurring-consumables revenue and the upgrade cycle for da Vinci systems. Read More.
• Neutral Sentiment: Analyst consensus shows meaningful upside (Zacks highlights ~29.7% average target upside), but that depends on execution and multiple expansion remaining intact. Read More.
• Neutral Sentiment: Long-form bullish pieces reiterate a multi-year growth story from da Vinci 5, Ion and software/services but don’t change near-term valuation concerns. Read More.
• Negative Sentiment: Cybersecurity incident (phishing-linked breach affecting internal systems) is the immediate catalyst for the share decline — investors will watch for customer impact, data exposure, and remediation costs. Read More.
• Negative Sentiment: Insider selling (recent EVP share sales) and management guidance calling for a deceleration in worldwide da Vinci procedure growth in 2026 could pressure near-term sentiment and valuation. Read More. • Read More.

Insider Buying and Selling

In related news, SVP Patricia L. Wadors sold 220 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $499.71, for a total value of $109,936.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Myriam Curet sold 105 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $493.95, for a total transaction of $51,864.75. The SEC filing for this sale provides additional information. Insiders sold 32,943 shares of company stock valued at $17,279,568 over the last 90 days. Insiders own 0.70% of the company’s stock.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $472.16 on Monday. The stock’s 50 day simple moving average is $513.26 and its 200-day simple moving average is $512.96. The stock has a market cap of $167.68 billion, a P/E ratio of 59.84, a P/E/G ratio of 3.64 and a beta of 1.66. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. The firm had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The firm’s revenue was up 18.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.21 earnings per share. As a group, research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ISRG shares. Barclays set a $712.00 target price on Intuitive Surgical and gave the company an “overweight” rating in a report on Monday, January 26th. Argus lowered their price target on Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Zacks Research upgraded Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 19th. HSBC increased their price objective on Intuitive Surgical from $644.00 to $653.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, TD Cowen raised shares of Intuitive Surgical to a “strong-buy” rating in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $615.86.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.